RxDoctor Payments Data

Terri Hinton, PA

Physician Assistant · Olathe, KSNPI 1972555985

Payments from drug & device makers

$1,291in general payments, 2019–2025

Across 95 payments — averaging $13.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$547
  • Supernus Pharmaceuticals, Inc.$228
  • AstraZeneca$141
  • Kowa Pharmaceuticals America, Inc.$83
  • Novo Nordisk$67
  • Idorsia Pharmaceuticals US Inc$67
  • plus $158 from 8 others

What the payments were for

  • Food & beverage$1,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,291 in reported general payments places this provider in the 70th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$18,109
Medicare patients
67
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$48,779
OzempicSemaglutide22$25,087
FarxigaDapagliflozin Propanediol20$25,069
JanuviaSitagliptin Phosphate23$21,899
Tresiba Flextouch U-200Insulin Degludec12$12,456
EliquisApixaban12$11,839
RybelsusSemaglutide12$11,300
VascepaIcosapent Ethyl23$11,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,818
Potassium Chloride74$5,277
Famotidine67$4,363
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen97$3,900
PremarinEstrogens, Conjugated15$2,903
SynthroidLevothyroxine Sodium32$2,672
Clonidine12$2,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$46$48,77942 claims
Novo NordiskOzempic, Rybelsus$67$36,38734 claims
AstraZenecaFarxiga$141$25,06920 claims
GSKTrelegy Ellipta$14$8,81813 claims
AbbVieSynthroid$547$2,67232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →